Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Recruiting

Early Phase 1

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Sponsor:

University of Chicago

Code:

NCT06171152

Conditions

Multiple Sclerosis

Long COVID

Long Covid19

Obese

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Not accepted

Interventions

Liraglutide Pen Injector [Saxenda]

Medication Diary

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-08. This information was provided to ClinicalTrials.gov by University of Chicago on 2024-07-31.